Cardiac and cancer testing help spur growth in immunodiagnostics market
This article was originally published in Clinica
The global market for immunodiagnostic products totalled $7.0 billion in 2006. The largest segment was general-purpose immunoassay systems, totalling $5.0 billion including reagents, consumables, equipment and service. This segment includes both stand-alone immunoassay analysers as well as immunoassay tests performed on integrated chemistry/immunochemistry systems. The segment is forecast to grow at 7.9% per year on average over the 2006-2011 period. Factors responsible for growth in the general-purpose segment include the continued trend for specialty immunoassay tests to be converted to general-purpose testing platforms, strong growth in tests such as cardiac marker assays and infectious disease tests that are performed on general-purpose systems, and growth in adoption of integrated chemistry/routine immunochemistry testing platforms.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.